# A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

> **NCT07298044** · PHASE4 · RECRUITING · sponsor: **Bayer** · enrollment: 50 (estimated)

## Conditions studied

- Transthyretin Amyloid Cardiomyopathy

## Interventions

- **DRUG:** Acoramidis

## Key facts

- **NCT ID:** NCT07298044
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-13
- **Primary completion:** 2027-12-25
- **Final completion:** 2027-12-25
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298044, "A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07298044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*